



## SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)  
Ph. : 040-23204230, 23204273  
Fax : 0091-40-23204273  
CIN : L24230TG1994PLC018786  
E-mail: sigachilaboratories@yahoo.co.in

Date: 14.09.2017

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
Vibgyor Towers, 4th Floor  
Plot No.62, G- Block, Opp Trident Hotel,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., 14<sup>th</sup> September, 2017 – Submission of unaudited financial results for the quarter ended 30th June, 2017 –Reg.

\*\*\*

We wish to inform you that the Board of Directors at its Meeting held today i.e. Thursday, 14th September, 2017 inter-alia considered and approved the Unaudited Financial Results of the company for the quarter ended 30th June, 2017.

The Limited Review of the aforesaid financial results have been done by the statutory auditors of the company M/s. Janardhanrao Deshmukh & Co., Chartered accountants, Hyderabad.

In this connection, please find enclosed the following

- Unaudited Financial Results of the company for the quarter ended 30th June, 2017.
- Limited review report issued by the statutory auditors of the company M/s. Janardhanrao Deshmukh & Co., Chartered accountants, Hyderabad

This is for your Information and Records.



Yours faithfully,  
For Sigachi Laboratories Limited

  
(Kuradia Ajay Kumar)  
Company Secretary & Compliance Officer

The Meeting Commenced at 11.30 A.M.,  
The Meeting Concluded at 12.30 P.M.,

Encl: As above

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, (formerly Jinnaram Mandal), Sangareddy District, (formerly Medak District), Telangana.

Tel No.: 040 - 23204230 / 23204273.

Website: www.slllab.com, Email: sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter Ended 30th June, 2017

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended	
		30.06.2017	30.06.2016
		(Un Audited)	(UnAudited)
1	Revenue from operations		
	Net Sales/ Income from Operations	47.20	63.72
2	Other Income	-	-
3	Total income (1+2)	47.20	63.72
4	Expenses		
	a) Cost of materials consumed	-	-
	b) Purchase of stock-in-trade	-	-
	c) Changes in inventories of finished goods, work in progress and stock -in- trade	-	-
	d) Employee benefits expense	6.35	5.40
	e) Finance costs	-	-
	f) Depreciation and amortisation	2.78	2.94
	g) Other expenditure	3.78	4.17
	Total expenses	12.91	12.51
5	Profit/(Loss) before exceptional items and tax (3-4)	34.29	51.21
6	Exceptional items	-	-
7	Profit/(Loss) before tax (5-6)	34.29	51.21
8	Tax expense		
	a) Current tax	4.25	3.43
	b) Deferred tax	0.55	0.79
9	Profit/(loss) for the period from continuing operations (7-8)	29.49	46.99
10	Profit/(loss) for the period from discontinuing operations	-	-
11	Tax expense of discontinuing operations	-	-
12	Profit/(loss) for the period from discontinuing operations (10-11)	-	-
13	Profit/(loss) for the period (9+12)	29.49	46.99
14	Other comprehensive income		
	a) (i) Items that will not be reclassified to profit or loss	24.87	69.36
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-
	Total other comprehensive income	24.87	69.36
15	Total Comprehensive income (13+14)	54.36	116.35
16	Paid-up equity share capital (face value Rs.10/- per share)	675.31	675.31
17	Earnings per equity share (Rs.)		
	- Basic	0.80	1.72
	- Diluted	0.80	1.72

Segment wise Revenue, Results and Capital Employed for the quarter ended 30th June, 2017

(Rs. in Lakhs)

Sl. No	Particulars	Quarter Ended	
		30.06.2017	30.06.2016
		(Unaudited)	(Unaudited)
1	Segment Revenue		
	a) Bulk Drugs and Intermediates	24.00	15.00
	b) Investments	23.20	48.72
	Total	47.20	63.72
	Less: Inter Segment Revenue	-	-
	Net sales/Income from operations	47.20	63.72
2	Segment Results Profit/(Loss) before tax and finance costs from each segment		
	a) Bulk Drugs and Intermediates	20.39	11.34
	b) Investments	23.20	48.72
	Total	43.59	60.06
	Less: (i) Finance costs	-	-
	(ii) Other Un-allocable expenditure net off	9.30	8.85
	(iii) Un-allocable income	-	-
	Total Profit Before Tax	34.29	51.21
3	Capital Employed		
	(Segment assets – Segment Liabilities)		
	a) Bulk Drugs and Intermediates	328.80	306.55
	b) Investments	1,514.29	1,289.16
	Total	1,843.09	1,595.71

NOTES:

- The above results were reviewed by the Audit Committee and taken on record and approved by the Board of Directors at their respective meetings held on 14.09.2017. The financial results for the quarter ended 30th June, 2017 have been subjected to limited review by the company's Statutory Auditors
- The Company has presented, for the first time, its financial results under Indian Accounting Standards ("Ind AS") from 1st April, 2017 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Financial Results for the Comparative Previous period have also been presented in accordance with the recognition and measurement principles of Ind AS 34.
- Reconciliation between financial results as previously reported under Previous GAAP and Ind AS for the quarter ended 30th June, 2016:

Particulars	Quarter Ended
	30.06.2016 (UnAudited)
Profit after tax under previous GAAP	46.21
Impact on deferred taxes	(0.79)
Increase in Other Comprehensive Income on account of fair value measurement of Equity instruments	69.36
Difference in gains on Investments on account of differences between previous GAAP and IND AS	1.57
Total Comprehensive Income under Ind AS	116.35

- The statement does not include Ind-As compliant results for the preceding quarter and previous year ended 31st March, 2017 as the same are not mandatory as per SEBI circular dated 5th July, 2016.
- The figures for the quarter ended 30th June, 2016 have been restated to comply with Ind AS to make them comparable with the current period. They have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that the final results provide a true and fair view of the Company's affairs. Further, they have been regrouped/reclassified/rearranged wherever necessary to conform with the current period presentations.

for Sigachi Laboratories Limited

Chairman and Managing Director  
DIN:00917498

Place: Hyderabad  
Date: 14-9-2017.

JANARDHANRAO DESHMUKH & CO.,  
CHARTERED ACCOUNTANTS

Flat No.304, Lumbini Apartments,  
Dharam Karan Road,  
Ameerpet, Hyderabad-500 016  
Tel No.: 040-23736293  
e-mail: [ljrao46@yahoo.com](mailto:ljrao46@yahoo.com)

To  
The Board of Directors  
Sigachi Laboratories Limited  
Hyderabad

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sigachi Laboratories Limited (the company) for the quarter ended 30<sup>th</sup> June, 2017 (the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting' (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We have not reviewed the accompanying financial results and other financial statements and other information for the quarter ended 30<sup>th</sup> June, 2016 which have been presented solely based on information compiled by the management and has been approved by the Board of Directors.

for Janardhan Rao Deshmukh & Co.,  
Chartered Accountants  
Firm Registration Number:005979S

(L. Janardhan Rao)  
Proprietor  
Membership No.18474

Place : Hyderabad  
Date : 14.09.2017